Generative design of de novo AAV vectors with unique serological profiles
The preprint abstract reports a variational autoencoder trained on natural AAV sequences to generate capsids. More than 255 designs were synthesized and tested in vitro. Seven transduced human cells at over 50% efficiency; four of those avoided neutralization by every AAV-reactive human serum sample tested, at the reported NT50 threshold below 1:50. This establishes in-vitro capsid properties, not in-vivo delivery or clinical efficacy. Review is limited to the abstract and original-server metadata.
Technology: Variational autoencoder (generative model of AAV capsid sequences)
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: More than 255 AI-generated capsid designs were synthesized and tested in vitro; seven transduced human cells above 50% efficiency and four avoided neutralizing antibodies in all reactive human sera.
- Still unknown: Review limited to the indexed abstract and publication metadata; full-paper methods and additional limitations were not assessed.
- AI role: A variational autoencoder learned AAV sequence constraints from natural sequences and generated functional capsid proteins de novo, with a second design campaign exploring uncertain regions.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A%2210.64898%2F2026.11.06.764881%22&resultType=core&format=json · https://api.biorxiv.org/details/biorxiv/10.64898/2026.11.06.764881
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.